Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

April 12, 2020/in Microarray

Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology [PDF] [DOI] [PubMed]

Tags: NGS

Share this entry

Share on Twitter
Share by Mail

https://utsw-sequencing-cores.org/wp-content/uploads/2022/12/utsw-master-logo-lg-300x92.png 0 0 Academic Web Pages https://utsw-sequencing-cores.org/wp-content/uploads/2022/12/utsw-master-logo-lg-300x92.png Academic Web Pages2020-04-12 00:00:002022-09-28 09:30:00Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions

A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency

Deep sequencing reveals a DAP1 regulatory haplotype that potentiates autoimmunity in systemic lupus erythematosus

Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA